Shopping Cart
0 Item in Cart

Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3e (HB)
Click for related books: Rosenberg

(80 Ratings)

Retail Price: 7592.00/-
Price: 6074.00/-
Inclusive all taxes
20.00% OFF
Sold By: Store4Doctors

Offer 1: Get 20.00% + Flat ₹ 50 discount on shopping of ₹ 1500
                use code:

Offer 2: Get 20.00% + Flat ₹ 150 discount on shopping of
                ₹ 5000 use code:

Free Shipping (for orders above ₹ 499)  *T&C apply.

In Stock Click For New Edition
Select Quantity :

Key Features
  • Third edition of the first ever book published on pediatric psychopharmacology from renowned editors
  • Incorporates current developments with regard to SSRIs, their indications and their safety issues, i
  • Addresses concerns about cardiovascular side effects of the new stimulant medications available, and
  • Features many tables, figures and pictorials, making it highly accessible and reader friendly.

This book fulfils an urgent need for an updated text on pediatric psychopharmacology. It takes a unique approach in discussing recent findings within the context of current issues, including economic and political ones. The book covers the emerging question of treating children who do not yet meet diagnostic criteria for psychosis, e.g, schizophrenia or bipolar disorder, but who are deemed to be at high risk. This is an active area of debate: such children are being treated in certain centers, while others reject this completely. The book addresses the antidepressant controversy, the placebo response and unique strategies for delineating this, and ways to optimize the differential between active medication and placebo. It reviews the impact of recent American Heart Association guidelines for monitoring children on stimulants and other psychotropics. It adheres closely to DSM-IV diagnostic criteria throughout. The book describes the use of newly approved drugs such as Lexapro for treating adolescent depression and the novel compound Intuniv. It covers the TADS and CAMS studies, which evaluated the use of SSRIs alone and in combination with cognitive behavioral therapy for adolescent depression. Other topics include treatment of bipolar disorders, the increasing popularity of generic equivalents, combination pharmacotherapy and the potential dangers of psychotropic medications.

More Details About Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3e (HB)
General Information
PublisherJohn Wiley
BindingHard Back
Publish YearJanuary 2012
Reviews of Pharmacotherapy of Child and Adolescent Psychiatric Disorders 3e (HB)
Average Rating

Write A Review


Top Reviews lists the most relevant product reviews only.